

OUR CONTRIBUTIONS TO THE FIGHT AGAINST COVID-19

EMD SERONO

MILLIPORE SIGMA

EMD ELECTRONICS

We are dedicated to serving patients, scientists and healthcare providers around the world – now more than ever.

PREVENTION

In March 2020

Stefan Oschmann and Wolfgang Ischinger issued a

5-point plan

for **pandemic preparedness**.

They first addressed the topic at the Munich Security Conference back in 2017.

In 2020

we offered a research grant of up to

€ **500,000**

per year for three consecutive years to **external research teams** working on pandemic preparedness projects.

Since October 2020 we are partnering with the Californian company **Mammoth Biosciences** for the development, scale-up and commercial production of a CRISPR-based Covid-19 diagnostic test.

In February 2021 we announced the expansion of our strategic partnership with BioNTech and will increase our supply volume of lipids needed for the **Pfizer-BioNTech vaccine**.


TREATMENT

We are a member of the **CARE** (Corona Accelerated R&D in Europe) consortium in order to advance research and future treatments. Studies are also underway to investigate whether existing treatments can be used.

Our compound **M5049 is being** clinically tested in a Phase II trial as a treatment for patients with Covid-19 pneumonia.

As a result of the acquisition of **AmpTec** at the start of 2021, we are strengthening our capacity for developing and manufacturing vaccines and treatments based on messenger ribonucleic acid (mRNA) technology.

Our Life Science business participates in the **MIT Pandemic Response CoLab**, which will help individuals and groups work together to solve practical problems created by the Covid-19 pandemic. By leveraging an open online collaboration platform, the CoLab mobilizes innovators, communities, businesses, and others to develop actionable solutions to real problems.



PRODUCTION

In December 2020 our company announced the **broadening of its manufacturing footprint** with a combined **40 million euro** investment at its Life Science production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, USA. These sites supply critical products to customers developing lifesaving therapies, including Covid-19 vaccines.

In March 2021 we announced to **accelerate** its European expansion plans for **single-use products** which are critical to manufacturing vaccines and lifesaving therapies. A **25 million euro** investment in Molsheim, France, will create **350 new jobs**. In addition, **capacity expansion activities** are underway at our single-use production site in **Wuxi, China**.

Even in the first phase of the pandemic in 2020, we maintained the **production and supply chains** of our Healthcare business sector across the globe in all affected regions and supplied more than **85 million patients** worldwide with their (non-Covid-19-related) medication.



GOOD TO KNOW

Our **liquid crystal technology** is used in X-ray imaging technologies, ventilators and monitors for keeping track of the vital signs of patients in intensive care units.

Our **electronic materials** help people all over the world to stay in contact and are **also used in the medical equipment** that is needed to detect and fight Covid-19.

FURTHERMORE

Our employees and the company donated around **140,000 euro** to **"Save the Children"** in the fight against Covid-19.

In more than **40 countries** we had multiple donation efforts, adding up to cash and goods worth **millions of euros**, including in-house 3D-printed face shields and disinfectant.

We donated **two million FFP2 masks**, e.g. in Germany, France, Brazil, the United States, Ethiopia, Ghana, Central America, Cameroon, Nigeria, Mexico, Lebanon, Mauritania to **support frontline healthcare workers**.

WE ARE INVOLVED IN...

> **50** vaccine projects > **35** testing solutions > **20** monoclonal antibodies, plasma products and antiviral drugs

EMPLOYEE HEALTH & SAFETY

A **Corporate Crisis Management Team** formed in **February 2020** provides global guidance on hygiene measures, travel and meeting restrictions adaptable to local needs.

A holistic **hygiene and social distancing concept** with comprehensive measures in place for our people on site including special arrangements for employees with pre-existing health conditions or childcare obligations.

We support **working from home** wherever possible.

We support **psychological counseling** for our employees in all countries, often 24/7, also for close relatives in need.



We are offering several **free-of-charge training elements** to support our employees in managing the Covid-19 crisis.

We produce **FFP2 protective face masks** at our Healthcare manufacturing site in Nantong, China, to deliver fully certified masks to our employees in Europe and Asia.

We are supporting our employees in **heavily affected countries**: In India, we are providing **two million euro for vaccinations and medical equipment**; vaccination programs are being prepared for Peru, Indonesia and the Philippines, among others.

EARLY MILESTONES

In 2019 we awarded **one million euro** to Pardis Sabeti and James Crowe, the winners of the **Future Insight Prize**, for outstanding research on the topic of **pandemic preparedness**.

In 2020 we partnered with **Jenner Institute** of the University of Oxford to develop a manufacturing process for a vaccine, which has been approved for emergency use in multiple countries. We also partnered with **Baylor College of Medicine** in Houston, Texas, to develop manufacturing platforms for two vaccines, which are in clinical trials.

To date, we have donated a total of **300,000 units** of interferon beta-1a (Rebif®)* to the **French Institut National de la Santé et de la Recherche Médicale (INSERM)** for a trial, the **World Health Organization (WHO)** for use in their global Solidarity trial, and the **US National Institute of Allergy and Infectious Diseases (NIAID)** for their ACTT 3 trial in combination with remdesivir.

* To date, our interferon beta-1a is not approved by any regulatory authority for the treatment of Covid-19 or for use as an antiviral agent.